Literature DB >> 16113462

Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality.

Don D Sin1, S F Paul Man.   

Abstract

Chronic obstructive pulmonary disease and other disorders, associated with reduced lung function, are strong risk factors for cardiovascular events, independent of smoking. Overall, when the lowest quintile of lung function, as measured by FEV1 is compared with the highest quintile, the risk of cardiovascular mortality increases by approximately 75% in both men and women. Having symptoms of chronic bronchitis alone increases the risk of coronary deaths by 50%. Reduced ratio of FEV1 to FVC by itself is a modest independent risk factor for coronary events, increasing the risk by 30%. However, if patients have ventricular arrhythmias, the risk of coronary events is increased twofold, suggesting that the cardiotoxic effects of obstructive airways disease are amplified in those who have underlying cardiac rhythm disturbances. In general, for every 10% decrease in FEV1, all-cause mortality increases by 14%, cardiovascular mortality increases by 28%, and nonfatal coronary event increases by almost 20%. These data indicate that chronic obstructive pulmonary disease is a powerful, independent risk factor for cardiovascular morbidity and mortality.

Entities:  

Mesh:

Year:  2005        PMID: 16113462     DOI: 10.1513/pats.200404-032MS

Source DB:  PubMed          Journal:  Proc Am Thorac Soc        ISSN: 1546-3222


  133 in total

1.  Preclinical vascular disease identifies smokers at risk for COPD.

Authors:  James D Crapo
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-04       Impact factor: 11.205

2.  Decreased Lung Function and All-Cause Mortality in HIV-infected Individuals.

Authors:  Matthew R Gingo; Mehdi Nouraie; Cathy J Kessinger; Ruth M Greenblatt; Laurence Huang; Eric C Kleerup; Lawrence Kingsley; Deborah K McMahon; Alison Morris
Journal:  Ann Am Thorac Soc       Date:  2018-02

Review 3.  [Comorbidities of COPD].

Authors:  H Watz; H Magnussen
Journal:  Internist (Berl)       Date:  2006-09       Impact factor: 0.743

4.  Relationship between coronary artery disease and pulmonary arterial pressure in patients with chronic obstructive pulmonary disease.

Authors:  Muntecep Asker; Selvi Asker; Ugur Kucuk; Hilal Olgun Kucuk; Bulent Ozbay
Journal:  Int J Clin Exp Med       Date:  2014-12-15

5.  Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary disease.

Authors:  Laurent Savale; Ari Chaouat; Sylvie Bastuji-Garin; Elisabeth Marcos; Laurent Boyer; Bernard Maitre; Mourad Sarni; Bruno Housset; Emmanuel Weitzenblum; Mireille Matrat; Philippe Le Corvoisier; Dominique Rideau; Jorge Boczkowski; Jean-Luc Dubois-Randé; Christos Chouaid; Serge Adnot
Journal:  Am J Respir Crit Care Med       Date:  2009-01-29       Impact factor: 21.405

6.  Airflow obstruction, atherosclerosis and cardiovascular risk factors in the AGES Reykjavik study.

Authors:  Gunnar Gudmundsson; Olof Birna Margretardottir; Martin Ingi Sigurdsson; Tamara B Harris; Lenore J Launer; Sigurdur Sigurdsson; Orn Olafsson; Thor Aspelund; Vilmundur Gudnason
Journal:  Atherosclerosis       Date:  2016-07-28       Impact factor: 5.162

7.  Chronic obstructive pulmonary disease: an update of treatment related to frequently associated comorbidities.

Authors:  Nicola J Sinden; Robert A Stockley
Journal:  Ther Adv Chronic Dis       Date:  2010-03       Impact factor: 5.091

Review 8.  Anesthetic considerations in candidates for lung volume reduction surgery.

Authors:  Neil W Brister; Rodger E Barnette; Victor Kim; Michael Keresztury
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

Review 9.  Comorbidities in chronic obstructive pulmonary disease.

Authors:  Wissam M Chatila; Byron M Thomashow; Omar A Minai; Gerard J Criner; Barry J Make
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

10.  Abnormal levels of circulating endothelial progenitor cells during exacerbations of COPD.

Authors:  Ernest Sala; Cristina Villena; Catalina Balaguer; Angel Ríos; Carlos Fernández-Palomeque; Borja G Cosío; Javier García; Aina Noguera; Alvar Agustí
Journal:  Lung       Date:  2010-01-14       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.